Buchumschlag

Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma

Daratumumab is a CD38-directed monoclonal antibody approved for treating multiple myeloma (MM). Propensity score matching (PSM) based on individual patient data (IPD) was conducted to compare overall survival (OS) and progression-free survival (PFS) for daratumumab versus real-world standard of care...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kumar, Shaji (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2019
In: Leukemia and lymphoma
Year: 2018, Jahrgang: 60, Heft: 1, Pages: 163-171
ISSN:1029-2403
DOI:10.1080/10428194.2018.1459609
Online-Zugang:Verlag, Volltext: https://doi.org/10.1080/10428194.2018.1459609
Verlag: https://www.tandfonline.com/doi/abs/10.1080/10428194.2018.1459609?journalCode=ilal20
Volltext
Verfasserangaben:Shaji Kumar, Brian Durie, Hareth Nahi, Ravi Vij, Meletios A. Dimopoulos, Efstathios Kastritis, Evangelos Terpos, Xavier Leleu, Meral Beksac, Hartmut Goldschmidt, Jens Hillengass, Zhuo Su, Brian Hutton, Chris Cameron, Imran Khan & Annette Lam
Beschreibung
Zusammenfassung:Daratumumab is a CD38-directed monoclonal antibody approved for treating multiple myeloma (MM). Propensity score matching (PSM) based on individual patient data (IPD) was conducted to compare overall survival (OS) and progression-free survival (PFS) for daratumumab versus real-world standard of care (SOC). IPD for patients with relapsed and refractory (RR) MM treated with daratumumab monotherapy were from the GEN501 and SIRIUS studies; IPD for patients treated with SOC were from an International Myeloma Working Group (IMWG) chart review of patients with RRMM. Prior to PSM, patients treated with daratumumab had significantly longer OS (median 20.1 vs. 10.1 months, hazard ratio [HR] = 0.51 [0.39-0.67]) and PFS (median 4.0 vs. 2.8 months, HR = 0.73 [0.58-0.92]) than patients treated with SOC therapies. After PSM, daratumumab maintained a significantly prolonged OS (19.9 vs. 9.2 months, HR = 0.44 [0.31-0.63]) and PFS (3.9 vs. 1.6 months, HR = 0.56 [0.42-0.74]) compared with SOC.
Beschreibung:Published online: 09 May 2018
Gesehen am 24.10.2019
Beschreibung:Online Resource
ISSN:1029-2403
DOI:10.1080/10428194.2018.1459609

Ähnliche Einträge